BOSTON, MA, September 18 – Biotech Policy Group, an industry leading healthcare regulatory policy and government relations consulting firm will be featured at the Anti-Infectives Rx Conference at Harvard Medical School in Boston on September 19, 2017 to discuss the industry outlook over the next five years.
Anti-Infectives Rx is an off-the- record networking forum featuring discussion panels from industry CEOs, life science leaders, key academics and investors. The conference focuses on issues facing the development of anti-infective, antiviral, and antibacterial therapies, and will discuss regulatory issues, sustainability, partnering, as well as microbiome and immunotherapy as the new wave of anti-infectives.
Anne Marie Finley, President of Biotech Policy Group, will be discussing trends in anti-infective product development, regulatory pathways unique to unmet medical needs and legislative incentives to spur innovation in the space with a panel of CEOs from BioVersys, Agile Sciences and Antibiotix. She was also a featured speaker at last year’s conference.
“I am honored to be presenting again at Harvard Medical School’s Anti-Infectives Rx with an esteemed panel of healthcare professionals and pharmaceutical executives. I look forward to discussing the historic difficulty in development of anti-infective drugs for rare, tropical and neglected diseases and the impact of new legislative and regulatory mechanisms to stimulate the pharmaceutical industry’s development of these critical products for crucial public health needs,” said Anne Marie Finley, president of Biotech Policy Group.
The Anti-Infectives RX Conference is an all-day event being held at the Joseph B. Martin Conference Center at Harvard Medical School on September 19, 2017. Biotech Policy Group will be presenting on the concluding panel at 4:00 pm eastern.
Biotech Policy Group specializes in developing regulatory and public policy solutions for pharmaceutical, biologic, diagnostic, medical device and food clients. Biotech Policy Group has extensive expertise in the development of products for rare diseases and unmet medical needs. Biotech Policy Group was founded in 2001 and has offices in Washington, DC and Milwaukee, WI.
Biotech Policy Group President Anne Marie Finley was named a Top 50 Global Thought Leader in Orphan Drugs and Rare Diseases by the World Orphan Drug Congress in 2014, after a 20 year career in orphan development in senior level positions at the US Food and Drug Administration, US Department of Health and Human Services, Celgene, GE Healthcare, Amersham and as a consultant to many biotech companies, academic medical centers and patient organizations.
More information on Biotech Policy Group can be found at BiotechPolicyGroup.com.
For more information about Biotech Policy Group, please contact:
Tim Vertz | firstname.lastname@example.org | 414.379.1677